(Q42653859)

4 November 2017

title

A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis (English)

1 reference

4 November 2017

1 reference

1 reference

Levy S

1

1 reference

4 November 2017

Furst K

series ordinal

2

1 reference

4 November 2017

Chern W

series ordinal

3

1 reference

4 November 2017

publication date

1 June 2001

1 reference

4 November 2017

published in

Clinical Therapeutics

1 reference

4 November 2017

volume

23

1 reference

4 November 2017

issue

6

1 reference

4 November 2017

page(s)

908-920

1 reference

Destructive procedures are the standard of care for treatment of actinic keratoses

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980078-3

7 January 2021

Clinical presentation of actinic keratoses and squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980078-3

7 January 2021

Managing actinic keratoses with retinoids

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980078-3

7 January 2021

Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980078-3

7 January 2021

Epidemiology of actinic keratoses and squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980078-3

7 January 2021

The treatment of actinic keratoses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980078-3

7 January 2021

New and emerging treatments for photoaging

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980078-3

7 January 2021

Further Studies With Topical 5-Fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980078-3

7 January 2021

The metabolism and pharmacology of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980078-3

7 January 2021

Cutaneous absorption and urinary excretion of 6-14C-5-fluorouracil ointment applicated in an ointment to healthy and diseased human skin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980078-3

7 January 2021

5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980078-3

7 January 2021

Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980078-3

7 January 2021

Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980078-3

7 January 2021

Can pharmacokinetic monitoring improve clinical use of fluorouracil?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980078-3

7 January 2021

A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980078-3

7 January 2021

Topical 5-fluorouracil solution in the treatment of warts—clinical experience and percutaneous absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980078-3

7 January 2021

10.1016/S0149-2918(01)80078-3

Identifiers

DOI

1 reference

4 November 2017

1 reference